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Background: Monitoring patients' experiences with antipsychotics may help to improve medication adher-
ence and outcome. We aimed to develop a shorter version of a comprehensive 74-item self-report question-
naire suitable for routine monitoring of desired and undesired effects of antipsychotics.
Methods: Included were patients with psychotic disorders from seven mental health care organizations in
The Netherlands, using antipsychotic medication, who completed the Subjects' Response to Antipsychotics
(SRA-74). Exploratory factor analysis (EFA) and similarity analysis based on mutual information were used
to identify the latent factor structure of the SRA. Items were reduced according to their metric properties
and clinical relevance upon consensus by an expert panel, using a Delphi procedure of three rounds. We
determined the internal consistency of the shorter version using Cronbach's alpha.
Results: SRA data of N = 1478 patients (mean age of 40 years, 31% females) were eligible for analysis. EFA
extracted thirteen factors from the SRA-74, including four factors for desired effects (e.g. recovery of psycho-
sis, cognition and social functioning) and nine factors for undesired effects (e.g. weight gain, ﬂattened affect
and increased sleep). Based on this solution 12 items were eliminated for statistical reasons. The expert panel
eliminated another 28 items with redundant content, resulting in a 34-item version. The SRA-34 includes 10
desired and 24 clinically relevant undesired effects. Both the subscales for desired and undesired effects have
a Cronbach's alpha coefﬁcient of 0.82.
Conclusions: The SRA-34 can be used to evaluate desired and undesired effects of antipsychotics in routine
clinical practice and research.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Schizophrenia is a chronic psychiatric disease, commonly necessi-
tating lifelong treatment with antipsychotics. Antipsychotics increase
the burden of disease, when they affect patients' physical, psychologi-
cal, sexual and social functioning (Voruganti et al., 2002). The patients'
experience of desired and undesired effects in response to antipsychotic
medication has been identiﬁed as a strong predictor of adherence
and outcome (Naber et al., 1994; Awad et al., 1996). Systematic moni-
toring of the balance between desired and undesired effects with31 50 3632772.
man@umcg.nl (R. Bruggeman),
umcg.nl (E.R. van den Heuvel),
enthe.nl (C.J. Slooff),
is).
rights reserved.antipsychotics is important for disease management (Budd et al.,
1996; Perkins, 2002). This requires a reliable and valid instrument.
Self-report is most optimal for the detection of often neglected, yet
disturbing experiences, such as sexual side effects (Peuskens et al.,
1998; Knegtering et al., 2003). Furthermore, self-report may save
time and costs in routine clinical practice. Existing self-rating scales
assessing experiences with antipsychotics either focus on quality of
life, like the Subjective Well-being on Neuroleptics (SWN) (Naber,
1995; Naber et al., 2001) and the Personal Evaluation of Transitions
in Treatment (PETiT) (Voruganti and Awad, 2002), or focus on
undesired effects, like the Liverpool University Neuroleptic Side Effect
Rating Scale (LUNSERS) (Day et al., 1995), and the Glasgow Antipsy-
chotic Side-effect Scale (GASS) (Waddell and Taylor, 2008), see
Wolters et al. (2009). In contrast, the Subjects' Response to Antipsy-
chotics (SRA) is a comprehensive assessment of 74 desired and
undesired effects attributed to antipsychotic medication, divided over
176 I.M. Lako et al. / Schizophrenia Research 147 (2013) 175–1808 subscales (Wolters et al., 2006). It is constructed of lay term expres-
sions, based on original patient statements which may be easier under-
stood than some of the clinical terms in the LUNSERS (Waddell and
Taylor, 2008). However, our own experience with the SRA-74 suggests
that patients especially those with concentration difﬁculties ﬁnd
it a long questionnaire with many questions addressing the same
clinical effect. Reducing the total number of items within the range
of other scales (about 30 items) (Day et al., 1995; Naber et al.,
2001; Voruganti and Awad, 2002; Waddell and Taylor, 2008)
would increase its feasibility for screening purposes. The subscale
structure of the SRA-74 has been established by a priori assumptions
(Wolters et al., 2006) and so far, the latent structure has not been
evaluated using more advanced statistical methods. The current study
therefore explored the latent structure of the SRA by exploratory factor
analysis (EFA) in a large cohort of patients with psychotic disorders.
The main aim was to develop a shorter version of the SRA, while main-
taining the latent structure.2. Methods
2.1. Questionnaires
The SRA-74 consists of one subscale of 24 desired effects, seven
subscales of 30 undesired effects of antipsychotics and 20 miscella-
neous undesired effects not belonging to a subscale; Appendix A1
(Wolters et al., 2006). The subscales have good internal consistency
(Cronbach's alpha 0.69–0.93) and test–retest reliability (Pearson's r cor-
relation 0.39–0.60). The SRA is rated on a 3-point scale (not present/yes,
mild/yes, severe). Patients received the SRA by mail to complete it
at home. In case of difﬁculties in completing the questionnaire they
received help from a trained nurse.
Trained nurses rated the level of psychotic symptoms using
the Positive and Negative Symptom Scale for Remission (PANSS-R)
(Opler et al., 2007). The patient's psychiatrist or case manager rated
psychosocial functioning using the Global Assessment of Functioning
scale (GAF; DSM-IV) (APA, 1994). A psychiatrist diagnosed each
patient according to the Diagnostic and Statistical Manual of Mental
Disorders—4th edition (DSM-IV) classiﬁcation system (APA, 1994).
Medication use over the past year was retrieved frommedical records
and conﬁrmed with the patient.2.2. Subjects
Patients with psychotic disorders receiving mental health care in
the north of The Netherlands, Amsterdam and Dordrecht were invited
to participate in the annual screening of their mental and physical
health by the Pharmacotherapy Monitoring and Outcome Survey
(PHAMOUS). Investigations were carried out between 2006 and
2010, in accordance with the latest version of the Declaration of
Helsinki. Included were patients with psychotic disorders (DSM-IV
codes 295.4–295.9, 297.1, 298.8 and 298.9), who used antipsychotics
for at least one month and completed the SRA (maximally 2 items
missing). In case a patient had participated in successive annual assess-
ments, the ﬁrst available measurement was selected for evaluation.2.3. Latent structure
Exploratory factor analysis (EFA) was used to identify the latent
factor structure of the SRA-74. Since one item of the SRA (about men-
struation) was completed only by female participants, factor analysis
was conducted on 73 items. In addition to EFA, we performed simi-
larity analysis to visualize the latent structure of the SRA-74 (for a
detailed description of the procedures, see Appendix A2).2.4. Item reduction
Within each factor, items with loadings of r b 0.30 on all factors,
cross-loading of r > 0.30 on two or more factors, or loading on a fac-
tor with a low main factor loading of r b 0.50 were considered
non-factorable (Comrey and Lee, 1992). Non-factorable items were
eliminated if there was no consensus about their clinical relevance
by the expert panel (see below). Factorable itemswith high factor load-
ings (r > 0.80) and/or a highly similar content within the same factor
were considered redundant. Of each pair of redundant statements,
the item with least speciﬁc, most ambiguous or multi-interpretable
(e.g. feelings that can be interpreted both literally and metaphorically)
content was eliminated upon consensus by the expert panel.2.5. Delphi procedure
A Delphi procedure consisting of three consecutive rounds was used
to reach consensus about the clinical relevance of the items in the ques-
tionnaire (Hsu and Sandford, 2007). The expert panel, all native Dutch
speaking, consisted of six psychiatrists, two neurobiologists and twopsy-
chologists. In the ﬁrst round, the panelists received the full questionnaire
including the results of the statistical analysis by e-mail. The experts
were asked 1) to rank order the clinical relevance of the non-factorable
items dropped for statistical reasons and 2) to mark redundant items
until maximally three items within each factor were retained. Clinical
relevance was deﬁned as being relevant for a patient to (dis)continue
antipsychotic therapy. In the second round, the panelists received a
new proposal for the shortened questionnaire, including a summary of
the arguments for item elimination or preservation. The experts were
asked whether they agreed with the proposed item reduction. If not,
they were asked to replace redundant items and to re-rank the clinical
relevance of each item. In the third and ﬁnal round, consensus was
reached about the ﬁnal version of the questionnaire. Items with consen-
sus rates of more than 75% agreement within the panel were retained.2.6. Statistics
Descriptive analyses and factor analysis were performed using Sta-
tistical Package for Social Sciences (PASW-18). Missing SRA-responses
were imputed for patients with maximally 2 items missing, using the
default settings of the multiple imputation method and random num-
ber generator (Mersenne Twister) of PASW-18. This cut-off was chosen
as maximally 2.7% of responses were missing per patient which can be
considered sporadically missing responses. Patients who completed all
items of the SRA were compared to patients with maximally 2 items
missing and to excluded patients (missing 3 or more items), with re-
spect to: gender, age, duration of illness and inpatient/outpatient status
using chi-square tests for categorical variables and Mann–Whitney
U tests for continuous variables.
Prevalence rates of SRA items were based on dichotomized scores
(no/yes). Factor analysis was conducted on the original 3-point scale
of the SRA. The responses on the desired effects were reversed prior
to factor analysis to obtain uniform scaling. The extraction method
for EFA was Generalized Least Squares. The rotation method was
Direct Oblimin with Kaiser Normalization, assuming a certain degree
of correlation between factors (e.g. increased sleep with sedation).
The number of factors to be retained was predeﬁned by the Kaiser's
criterion (eigenvalues ≥ 1). Kaiser-Meyer-Olkin (KMO) and Bartlett's
tests for sphericity were calculated to test whether the relationships
among variables in the sample are adequate for factor analysis.
The internal consistency of the ﬁnal version of the SRA was cal-
culated for the factorable items within the desired effects subscale
and undesired effects subscale. A Cronbach's alpha ≥ 0.80 indicates
good internal consistency (Streiner, 2003).
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3.1. Subjects
The number of patients included for evaluation was n = 1478
(66%) out of n = 2241 patients with psychotic disorders receiving
routine outcome assessments in the selected mental health care orga-
nizations between 2006 and 2010. Excluded were n = 142 (6%)
patients not using antipsychotics at the time of the interview, and
n = 621 (28%) patients having three or more SRA-items missing. In
the included sample, no systematic patterns were observed among
missing SRA-items and no items had more than 5% missing values.
Hence 325 (0.3%) missing values were imputed for those patients
with maximally 2 missing SRA-items (n = 272). Included patients
(n = 1478) had a mean age of 40.1 (SD 11.4) years and consisted
of n = 462 (31.3%) females (Table 1). Patients missing maximally 2
items had similar characteristics as patients without missing items
(n = 1206) except for a longer duration of illness (respectively 15.6
versus 13.5 years; p b 0.05). Excluded patients (n = 621) had a similar
duration of illness than patients withoutmissing items (n = 1206), but
were on average 4 years older (43.9 versus 39.9 years; p b 0.001),
consisted of relatively more female (38.6% versus 31.1%; p b 0.001)
and admitted patients (36.7% versus 28.3%; p b 0.001).
On average, patients attributed 13 (56%) out of 24 desired effects
to antipsychotics, compared to 18 (38%) out of 50 undesired effects.
Patients most frequently reported the desired effects of the SRA-74,
including ‘My emotions have returned’ (93%), ‘My memory has im-
proved’ (92%) and ‘I am more active’ (90%); most frequently reported
undesired effects were ‘I need more sleep’ (62%), ‘My weight has
increased’(60%) and ‘I get physically tired more easily’ (57%). All
other statements had a prevalence rate above 5%.3.2. Latent structure
Exploratory factor analysis extracted fourteen latent factors from
the 73 SRA-items, explaining a total variance of 58% (Table 2). The
correlation matrix of the data was considered factorable because
the EFA solution passed the Kaiser-Meyer-Olkin (KMO) test with a
value of >0.60 and the Bartlett's test of sphericity was signiﬁcantTable 1
Patient characteristics (n = 1478).
Sample (n = 1478)
N or mean % or SD
Gender (female) 462 31%
Age (years) 40.1 11.4
Duration of illness (years) 13.9 9.9
PANSS-positive 2.1 1.0
PANSS-negative 2.3 1.1
GAF symptoms 53.0 14.1









Other antipsychotic 254 17%
Combinations 303 21%
Number of co-medications 2.0 2.2
Reported desired effects (of 24 items) 13 56%
Reported undesired effects (of 50 items) 18 37%
Valuesweremissing for the following variables: duration of illness (n = 302; 14%), PANSS
(n = 75; 3%), GAF symptoms (n = 365; 17%) and GAF functioning (n = 544; 25%).(p b 0.001). All factors had high main factor loadings (0.58–1.00),
except for factor 13 (0.31). Factor 13 consisted of items with hetero-
geneous content and low factor loadings.
Visual inspection of the similarity matrix gave comparable results
as our exploratory factor analysis. All items with high factor loadings
shared a relevant degree of mutual information (similarity). Within
each factor, at least two items shared an amount of I > 0.20 mutual
information, except for factor 13 (Appendix A3). The items within
factor 13 displayed no sign of mutual dependence. Those items may
have converged in an artiﬁcial factor because they had low preva-
lence rates in common. Thus only factors 1 to 12 and factor 14 were
deemed reliable.
3.3. Item reduction
The number of items of the questionnaire was reduced to 52 after
the ﬁrst Delphi round of the expert panel and to 34 items after the
second round. In total, 23 items were identiﬁed as non-factorable,
see Fig. 1. Of those, 11 items were retained because of their clinical
relevance. Of the 52 factorable items, 28 redundant items were elim-
inated upon consensus of the expert panel. For example, #33 ‘My
feelings have returned’ was considered ambiguous and #11 ‘My
thoughts are calmer’ could be substituted by the more speciﬁc state-
ment #03 ‘I can think more clearly’. Similarly, the statements #16 ‘I
think more slowly’ and #50 ‘I move more slowly’ were considered
redundant to #13 ‘I react more slowly’. Some of the items were elim-
inated because they may be stigmatizing or evoke socially desired
answers, e.g. #70 ‘My sex drive is too low’; or because the statement
may be dependent on external factors such as the potentially limited
social network of inpatients, e.g. #36 ‘I have more difﬁculty keeping
up with conversations’. After the third Delphi round, consensus was
obtained about the 34-item questionnaire (Appendix A4), consisting
of 10 desired and 24 undesired experiences with antipsychotics.
3.4. Internal consistency of SRA-34
The internal consistency was acceptable for the desired subscale
(Cronbach's α = 0.82; 9 factorable items), as well as for undesired
subscale (α = 0.82; 14 factorable items) of the SRA-34.
4. Discussion
The SRA-34 is a unique questionnaire to measure a combination of
relevant self-reported desired and undesired effects in response to
antipsychotic medication. This is the short version of the SRA-74
questionnaire retaining the latent structure by covering 10 desired
and 24 undesired effects of antipsychotics. The SRA-34 is internally
consistent, having Cronbach's alpha values within the range of the
previously reported values for the subscales of the SRA-74 (Wolters
et al., 2006). Thus the SRA-34 can be considered a quick and reliable
instrument to guide pharmaco-therapeutic treatment in clinical
practice.
Exploratory factor analysis of the SRA-74 revealed new symptom
dimensions, in addition to the original subscale structure as proposed
by Wolters et al. (2006). First, desired effects were divided into
four factors (recovery from psychosis, improvement in cognition,
attention and social functioning). Second, we identiﬁed depressive
symptoms as a factor, independent of other emotional experiences.
The other factors remained the same (increased sleep, appetite and
weight, slowed down behavior, sexual problems, EPS, social with-
drawal and ﬂattened affect). Similarity analysis was useful in identify-
ing a number of items that did not belong to any of the factors, such as
‘dry mouth’ and ‘increased salivation’. Of those, experts retained the
most clinically relevant items in the SRA-34 according to the Delphi
consensus method.
Table 2




1. Appetite 19. I have an increased appetite 1.098 49%
32. I am hungry more often 0.689 47%
2. Slowed down 16. I think more slowly 0.596 44%
13. I react more slowly 0.554 52%
50. I move more slowly 0.431 44%
26. I can't remember well 0.419 45%





03. I can think more clearly 0.761 77%
04. I feel calmer 0.711 66%
02. I am more stable 0.666 63%
05. I am able to follow
conversations better
0.662 78%
01. I feel more like myself 0.631 79%
11. My thoughts are calmer 0.537 74%
12. I feel less confused *0.414 72%
35. I havemore control overmy thoughts 0.304 80%
30. I am less irritable b0.30 85%
4. Weight gain 46. I have gained too much weight −0.958 55%
60. My weight has increased −0.898 60%
66. I am less ﬁt b0.30 48%
5. Recovery
social
63. Dealing with others is easier −0.871 86%
61. I dare to make contact with
people again
−0.803 86%
64. I have more interest in my
surroundings
−0.709 86%
71. I am better at holding
conversations
−0.603 88%
62. I feel physically healthier −0.377 88%
6. Sexual
problems
70. My sex drive is too low −0.884 31%
17. My sex drive has decreased −0.791 42%





10. I sleep too much 0.784 49%
51. I need more sleep 0.715 62%
58. I have more difﬁculty waking up 0.622 48%
72. I can sleep better −0.412 71%
25. I feel more drowsy 0.338 55%
24. I get mentally tired more quickly b0.30 52%
8. EPS 41. My muscles are more tense 0.798 31%
48. My muscles are more stiff 0.689 36%
54. I have more tremors 0.385 27%
56. I have more trouble sitting still b0.30 30%
67. I have a dry mouth more often b0.30 36%
9. Social
withdrawal
68. I have less energy for socializing 0.715 38%
23. I am less interested in socializing 0.590 34%
36. I have more difﬁculty keeping up
with conversations
0.475 37%
37. I am less spontaneous 0.389 38%
43. I get physically tired more easily 0.330 57%
73. I am more detached b0.30 30%
10. Flattened
affect
09. My emotions are dull 0.866 54%
14. My emotions are too dull 0.800 44%
40. I am less emotional 0.567 42%
69. My thoughts are subdued b0.30 53%
07. My mind is blank more often b0.30 36%
22. I am less creative b0.30 40%
11. Recovery
psychosis
49. I am less psychotic 0.652 60%
52. I hear fewer voices 0.458 73%
18. I am less anxious 0.307 80%
12. Recovery
attention
28. I am more active 0.594 90%
29. My memory has improved 0.528 92%
27. I can concentrate better *0.471 87%
34. I feel happier 0.463 89%
33. My feelings have returned 0.320 93%
20. I am more conﬁdent b0.30 84%
38. My sex drive has increased b0.30 9%
13. Miscellaneous 21. I black-out more often 0.307 20%
42. I have increased salivation b0.30 36%
44. I am dizzy more often b0.30 31%
57. My vision is more blurred b0.30 30%
59. I am nauseous more often b0.30 18%
45. I am constipated more often b0.30 20%
53. I leak urine more often b0.30 20%





14. Depressive 06. I feel more depressed −0.584 20%
15. I feel down −0.578 33%
08. I feel more restless −0.450 23%
39. I am more irritable −0.301 20%
31. I get psychotic symptoms b0.30 11%
Female only 74. I menstruate less often 19%
Generalized Least Squares factor analysis with Direct Oblimin Rotation identiﬁed 14
latent factors. Cross-loadings of item #12 on factor 11 (0.384) and item #27 on factor
3 (0.327) were marked by an asterisk (*). Item #74 was for females only and
therefore not included in factor analysis. EPS = Extrapyramidal motor symptoms.
178 I.M. Lako et al. / Schizophrenia Research 147 (2013) 175–180What is the place of the SRA-34 in comparison with existing
instruments? The LUNSERS (Day et al., 1995) and GASS (Waddell
and Taylor, 2008) comprise detailed physical side effects. The
SRA-34 not only contains important physical side effects, but also
measures psychological effects of antipsychotics, such as emotional,
cognitive and social functioning. The SWN and PETiT questionnaire
typically cover some of the latter psychological effects (e.g. My think-
ing is difﬁcult and slow), as well as some desired subjective experi-
ences with antipsychotics similar to the SRA-34 (e.g. I ﬁnd it easy
to keep in touch with people around me) (Naber et al., 2001;
Voruganti and Awad, 2002), but no physical side effects. The SRA-34
can be used for a quick yet comprehensive evaluation of the patients'
experiences with antipsychotics. Experiences in response to new
medication can be evaluated by assessment of the SRA-34 before
and after switching antipsychotics in daily clinical practice or clinical
trials. Completing the SRA-34 should take a patient on average
5–10 min, about half the time needed to complete the SRA-74
(Wolters et al., 2006). Since we did not change the wording or add
new items, we assume that the test–retest reliability of the SRA-34
is comparable with the original version. A next step in the develop-
ment of the SRA-34 would be to test the feasibility in clinical practice
and to validate the questionnaire by evaluating the association
with clinical outcomes, e.g. whether (un)desired effects are predic-
tive for antipsychotic non-adherence, switching, relapse psychosis
or hospitalization.
A strong point of the current study is that our analysis was based
on a large sample of patients with psychotic disorders using a wide
range of antipsychotics and doses. Although we had a high response
rate, responding patients were slightly younger and more likely to
be male and treated as outpatients. This would suggest that some
patient groups such as elderly and inpatients had more difﬁculties
in completing the questionnaire. However, we believe that the exclu-
sion of these patients did not lead to major bias of the results, as the
current cohort appears to be representative for mental health practice
with similar prescribing patterns and exploratory factor analysis is a
robust method, especially in large samples. By reducing the SRA to
34 items, we hope that all patients will be able to complete the SRA.
An inherent limitation of the current study is that patients may
have difﬁculties in distinguishing antipsychotic effects from symp-
toms associated with the illness or effects of co-medication. This
remains an important and challenging question for clinicians in
daily practice. But because of the large sample size, we believe it un-
likely that this introduced systematic bias in our analysis. Another
possible limitation of the study was that we applied exploratory
factor analysis to a three-point scale (SRA-74), which could lead to
an overestimation of the number of factors (Woods, 2002). We min-
imized this risk by selecting the Generalized Least Squares method
of EFA. Furthermore, the visual representation of the latent structure
(by means of similarity analysis based on mutual information)
enabled us to detect artiﬁcial correlations.
In the clinical situation, the SRA-34 can be used to discuss the bal-
ance between desired and undesired effects of antipsychotics with the
Fig. 1. Overview of SRA items eliminated in sequential steps of the analysis.
179I.M. Lako et al. / Schizophrenia Research 147 (2013) 175–180patient. In line with previous studies, our patients were rather satisﬁed
with their antipsychotics (Hofer et al., 2002; Freudenreich et al.,
2004). Asking patients to recall the beneﬁcial effects of antipsychotics
(e.g. from treatment-free periods) may support treatment adherence
in an indirect manner (Tranulis et al., 2011). Insight in the patients'
appraisal of antipsychotics may help the clinician to understand the
patients' attitude towards medication and reinforces the process of
shared decision making (Goff et al., 2010). Monitoring desired and
undesired effects could thereby prevent relapse psychosis (Valenstein
et al., 2002; Weiden et al., 2004) and an increase in costs associated
(Gilmer et al., 2004). To conclude, we developed a quick and compre-
hensive tool to assess desired and undesired effects attributed to anti-
psychotics, feasible for use in routine clinical practice and clinical trials.
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